Comparison of DRB sequence‐based typing using different strategies

Voorter, Christina E.M.; Rozemuller, Erik H.; Bruyn-Geraets, D. De; Zwan, Anne Wil van der; Tilanus, Marcel G.J.; Berg‐Loonen, Ella M. van den

doi:10.1111/j.1399-0039.1997.tb02781.x

Cited by 77 publications

(70 citation statements)

References 10 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amplification and sequencing of HLA class I and class II were performed as described previously. 11,12 Transplantation regimen, graft-versus-host disease prophylaxis and supportive therapy All three patients received conditioning with fludarabine (30 mg/m 2 /day on six consecutive days), intravenous treosulfan (12 g/m 2 /day on three consecutive days), and intravenous melphalan (140 mg/m 2 /day once). The preparative regimen included CAMPATH-1H (0.1 mg/kg/day on two consecutive days) for the bone marrow recipients and 2.5 mg/kg/day ATG (Genzyme) for the cord blood recipient.…”

Section: Patients Materials and Methodsmentioning

confidence: 99%

Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman–Diamond syndrome

Sauer

Zeidler

Meissner

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only definitive treatment for severe bone marrow dysfunction and clonal disorders in patients diagnosed with Shwachman-Diamond syndrome (SDS).In an attempt to minimize regimen-related toxicity (RRT), we have initiated a fludarabine/treosulfan/ melphalan-based pilot protocol avoiding the combination of busulfan and cyclophosphamide. Median age at transplantation was 9.6 years (range 1.5-17 years). All three patients received conditioning with fludarabine (30 mg/m 2 / day Â 6), treosulfan (12 g/m 2 /day Â 3) and melphalan (140 mg/m 2 /day Â 1). CAMPATH-1H (0.1 mg/kg Â 2) was added in two cases, while rabbit ATG (Genzyme; 3 Â 2.5 mg/kg) was given to the cord blood recipient. One patient was transplanted with a non-manipulated marrow graft from an HLA-identical sibling, one with a marrow graft from a 10/10 matched unrelated donor, and one with a 9/10 matched unrelated umbilical cord blood (UCB) unit. Mean cell doses given were 3.6 Â 10 8 nucleated cells/ kg BW for the bone marrow recipients and 4.2 Â 10 7 nucleated cells/kg BW for UCB recipient. Overall, two of three patients are alive and display 100% donor chimerism. Acute graft-versus-host disease grade II was seen in one patient, while no GVHD exceeding grade I occurred in the remaining two.

show abstract

Section: Patients Materials and Methodsmentioning

confidence: 99%

Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman–Diamond syndrome

Sauer

Zeidler

Meissner

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…For sequencing a solid phase approach was used as described previously using the Autoread Sequencing kit from Pharmacia Biotech (Uppsala, Sweden). 19,20 Typing was performed using Pharmacia Typing Software.…”

Section: Hla-dpb1 Sequence-based Typingmentioning

confidence: 99%

“…Subsequently, to determine whether HLA-DPB mismatches were responsible for the induction of aGVHD, HLA-DPB was analysed by a sequence-based typing method. 19,20 Furthermore, HTLp-f and CTLp-f were determined to investigate whether the presence of alloreactive T cells before transplantation was predictive for development of aGVHD after BMT. Our data show that neither the functional assays (HTLp-f/CTLp-f/MLC) nor detailed HLA typing is predictive for the development of aGVHD in recipients of a partially T cell-depleted HLA-identical sibling graft.…”

mentioning

confidence: 99%

Helper and cytotoxic T cell precursor frequencies are not predictive for development of acute graft-versus-host disease after partially T cell-depleted HLA-identical sibling BMT

Meer¹,

Allebes²,

Voorter

et al. 1998

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Despite the use of partially T cell-depleted grafts, 20% of the recipients of an HLA-identical sibling marrow graft develop aGVHD уII. This indicates that the current method for selecting a sibling donor, ie serological typing for HLA-A, B and DR, and a mixed lymphocyte culture (MLC) or molecular typing for HLA-DRB/DQB, is not predictive for aGVHD. In order to optimise our selection procedure, we retrospectively analysed patients who developed aGVHD уII by means of sequencing based typing for HLA-DPB and frequency analysis of alloreactive helper and cytotoxic T lymphocyte precursors (HTLp-f and CTLp-f). Patients who did not develop aGVHD or developed aGVHD grade I served as controls. Retrospective typing for HLA-DPB revealed only a single disparity in the group with aGVHD уII, indicating that mismatches for antigens other than HLA are the major cause of aGVHD in these patients. Furthermore, in our patient group, neither HTLp-f nor CTLp-f were predictive for development of aGVHD indicating that these assays in their current set-up are insufficiently sensitive to predict aGVHD in BMT with a partially T cell-depleted graft. We conclude, that HLA-identical siblings can be identified by means of serological typing for HLA-A and B and intermediate resolution molecular typing for DRB and DQB, but that for the prediction of aGVHD cellular tests with higher sensitivity and specificity as compared to the currently used HTLp-f and CTLp-f assays need to be developed. Keywords: bone marrow transplantation; HLA-identical sibling; cytotoxic T cell precursor frequency; helper T cell precursor frequency; HLA-DP Alloreactive T cells present in the allogeneic marrow graft are the initiators of acute graft-versus-host disease (aGVHD) after allogeneic bone marrow transplantation (BMT). Matching for human leukocyte antigens (HLA) is Correspondence: Dr A van der Meer, Transfusion Service, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands Received 9 May 1998; accepted 28 July 1998 therefore crucial to reduce the incidence of aGVHD. As the HLA gene cluster is inherited in a Mendelian fashion, HLA identity between patient and donor can be achieved by using sibling donors who have inherited the same HLA haplotypes. However, 20-40% of these patients still develop moderate to severe aGVHD. 1 It would obviously be a great achievement if this risk could be identified before transplantation, in order to either search for a more histocompatible (sibling) donor or alternatively, to intensify GVHD prophylaxis.The current procedures used for the identification of HLA-identical siblings are largely based on serological typing of HLA-A, B and DR, whereby class II identity is confirmed either by a mixed lymphocyte culture (MLC) or by molecular typing for HLA-DRB and DQB. This selection procedure does not take into account the following two aspects: firstly, although patient and sibling donor have inherited the same HLA haplotypes, it has become apparent that due to recombination, HLA-DP mismatches can be present in ...

show abstract

“…Generation of antigen-specific T cells HLA A Ã 0201 and DRB1 alleles were genotyped by PCR amplification and sequencing (8,9) After two to four rounds of stimulation, antigen-specific T cells were plated in limiting dilution, and expanded with 10 mg/mL PHA (Sigma), irradiated allogeneic PBMCs, and 10 U/mL IL2. To test for specificity, 10 mg/mL HLA class I antibody (W6/32; AbD Serotec) was used to block the interactions between T cells and T2 cells in the presence of peptides.…”

Section: Elispot Assaymentioning

confidence: 99%

Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma

Zhou

Gupta

et al. 2015

Cancer Immunology Research

View full text Add to dashboard Cite

The augmentation of high-titer antibodies to ATP6S1 is associated with favorable clinical outcomes in patients who received vaccination with autologous, irradiated tumor cells engineered to secrete GM-CSF and allogeneic bone marrow transplantation. Cellular immune responses to ATP6S1 are unknown. To define its role as an immune target, examination of cellular responses to ATP6S1 and immunity related to current therapies such as checkpoint blockade is needed. We used an overlapping peptide library representing the full-length ATP6S1 protein to screen for cellular responses from the peripheral blood of patients with stage III and IV melanoma. Reactive peptide pools were used to determine the individual peptide activity and epitopes. Recombinant ATP6S1 protein was used in an ELISA to assess potential correlation with humoral immune responses and changes in immunity related to CTLA-4 blockade with ipilimumab in these patients. We observed a broad array of CD4 þ and CD8 þ cellular responses against ATP6S1, including the identification of several MHC class I and II ATP6S1 epitopes. The generation of specific CD4 þ and cytotoxic T cells revealed potent functional capability elicited by ipilimumab treatment in patients with metastatic melanoma, which revealed potent functional capability, including cytokine production, proliferation responsiveness to melanoma cell lines, and tumor-cell killing. Furthermore, the augmented humoral immune responses to ATP6S1 as a function of ipilimumab treatment were associated with beneficial clinical outcomes. These results support the continued development of ATP6S1 as a biomarker and therapeutic target. Cancer Immunol Res; 3(1); 59-67. Ó2014 AACR.

show abstract

Comparison of DRB sequence‐based typing using different strategies

Cited by 77 publications

References 10 publications

Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman–Diamond syndrome

Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman–Diamond syndrome

Helper and cytotoxic T cell precursor frequencies are not predictive for development of acute graft-versus-host disease after partially T cell-depleted HLA-identical sibling BMT

Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma

Contact Info

Product

Resources

About